Points International Announces Results of Annual General Meeting
TORONTO, May 13, 2021 (GLOBE NEWSWIRE) -- Points International Ltd. (TSX: PTS) (Nasdaq: PCOM) (“Points” or the “Company”), the global leader in powering loyalty commerce, announced today that all resolutions put to the annual general meeting of shareholders held on May 12, 2021 were passed, including the reappointment of the Company’s directors.
The following votes were received with respect to each director nominee:
Number of Shares For | Number of Shares Withheld | |
David Adams | 7,615,600 | 1,097,913 |
Christopher Barnard | 8,128,533 | 584,980 |
Michael Beckerman | 7,517,054 | 1,196,459 |
Bruce Croxon | 7,513,054 | 1,200,459 |
Robert MacLean | 8,392,701 | 320,812 |
Jane Skoblo | 8,708,691 | 4,822 |
John Thompson | 7,024,390 | 1,689,123 |
Leontine van Leeuwen-Atkins | 8,704,170 | 9,343 |
In addition, shareholders voted in favor of the reappointment of KPMG LLP as the auditors of the Company. The following votes were received with respect to the resolution:
Number of Shares For | Number of Shares Withheld | |
Reappointment of Auditors | 9,717,307 | 105,307 |
About Points International Ltd.
Points, (TSX: PTS) (Nasdaq: PCOM) is a trusted partner to the world’s leading loyalty programs, leveraging its unique Loyalty Commerce Platform to build, power, and grow a network of ways members can get and use their favourite loyalty currency. Our platform combines insights, technology, and resources to make the movement of loyalty currency simpler and more intelligent for nearly 60 reward programs worldwide. Founded in 2000, Points is headquartered in Toronto with teams operating around the globe.
For more information, visit Points.com.
Investor Relations Contact:
Cody Slach and Jackie KeshnerGateway Investor Relations 1-949-574-3860[email protected]
Source: Points International, Ltd.Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ParaZero Integrates its Safety Technology into Draganfly’s Commander 3XL Drones for Home Hospital Delivery and Emergency Response
- HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
- Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!